Literature DB >> 3908123

High performance liquid chromatographic determination of moxalactam in human plasma and cerebrospinal fluid.

J Nielsen, G Karlaganis, H M von Hattingberg, U B Schaad.   

Abstract

A sensitive and reproducible method for the measurement of moxalactam in plasma and cerebrospinal fluid is described. Plasma proteins were removed by precipitation with ice-cold methanol at pH 5.6 and centrifugation. The supernatant was analysed by HPLC on a mu-Bondapack/phenyl column, with a mobile phase of acetonitrile/water/PIC Reagent A (20/80/1), and detection at 280 nm. The calibration curve was linear for plasma concentrations from 10 micrograms/ml to 60 micrograms/ml. Reproducibility was 4.7% (coefficient of variation) for within-day analysis and 13.8% for day-to-day analysis. Plasma concentrations in 9 moxalactam-treated patients with severe infections ranged from 0.9 micrograms/ml to 409 micrograms/ml. Individual pharmacokinetic parameters were calculated using a personal computer. In selected cases moxalactam concentrations were also determined in cerebrospinal fluid and tracheal aspirates.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3908123     DOI: 10.1007/bf00547427

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  26 in total

1.  Activity, stability, and pharmacology of the epimers of moxalactam.

Authors:  R Wise; N Wright; P J Wills
Journal:  Rev Infect Dis       Date:  1982 Nov-Dec

2.  In vitro evaluation of LY127935 (6050S) compared with cefotaxime, eight other beta-lactams and two aminoglycosides.

Authors:  A L Barry; C Thornsberry; R N Jones
Journal:  J Antimicrob Chemother       Date:  1980-11       Impact factor: 5.790

3.  Measurement of serum and tissue concentration of moxalactam using high pressure liquid chromatography.

Authors:  W F Diven; B D Obermeyer; R L Wolen; V L Yu; J Lyon; J Zuravleff
Journal:  Ther Drug Monit       Date:  1981       Impact factor: 3.681

4.  Pharmacokinetics of moxalactam in patients with normal and impaired renal function.

Authors:  G R Aronoff; R S Sloan; F C Luft
Journal:  J Infect Dis       Date:  1982-03       Impact factor: 5.226

5.  Developmental pharmacokinetics of moxalactam.

Authors:  M D Reed; S C Aronoff; C M Myers; M P Husak; J S Bertino; J L Blumer
Journal:  Antimicrob Agents Chemother       Date:  1983-09       Impact factor: 5.191

6.  Moxalactam treatment of serious infections primarily due to Haemophilus influenzae type b in children.

Authors:  S L Kaplan; E O Mason; S J Kvernland; E M Loiselle; R D Feigin
Journal:  Pediatrics       Date:  1983-02       Impact factor: 7.124

7.  Pharmacokinetic and clinical evaluation of moxalactam in infants and children.

Authors:  R Latif; M C Thirumoorthi; J A Buckley; D M Kobos; M K Aravind; R E Kauffman; A S Dajani
Journal:  Dev Pharmacol Ther       Date:  1981

8.  Susceptibility of anaerobic bacteria to nine antimicrobial agents and demonstration of decreased susceptibility of Clostridium perfringens to penicillin.

Authors:  T J Marrie; E V Haldane; C A Swantee; E A Kerr
Journal:  Antimicrob Agents Chemother       Date:  1981-01       Impact factor: 5.191

9.  Clinical evaluation of a new broad-spectrum oxa-beta-lactam antibiotic, moxalactam, in neonates and infants.

Authors:  U B Schaad; G H McCracken; N Threlkeld; M L Thomas
Journal:  J Pediatr       Date:  1981-01       Impact factor: 4.406

10.  Moxalactam pharmacokinetics during hemodialysis.

Authors:  G R Aronoff; R S Sloan; S A Mong; F C Luft; S A Kleit
Journal:  Antimicrob Agents Chemother       Date:  1981-04       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.